These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34994084)

  • 1. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
    Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
    ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
    Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
    Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
    Adayev T; Wegiel J; Hwang YW
    Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
    Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
    ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
    Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
    J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of β-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes.
    Guan L; Li A; Song P; Su W; Zhang S; Chen J; Jiao X; Li W
    Bioorg Chem; 2024 Oct; 151():107676. PubMed ID: 39068716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
    Tarpley M; Oladapo HO; Strepay D; Caligan TB; Chdid L; Shehata H; Roques JR; Thomas R; Laudeman CP; Onyenwoke RU; Darr DB; Williams KP
    Eur J Pharm Sci; 2021 Jul; 162():105821. PubMed ID: 33781856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
    Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
    J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
    Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
    Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
    FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD).
    Gehlot P; Pathak R; Kumar S; Choudhary NK; Vyas VK
    Bioorg Med Chem; 2024 Nov; 113():117925. PubMed ID: 39357433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
    Yoon HR; Balupuri A; Choi KE; Kang NS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
    Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.
    Abbassi R; Johns TG; Kassiou M; Munoz L
    Pharmacol Ther; 2015 Jul; 151():87-98. PubMed ID: 25795597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
    Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
    Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
    Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
    J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.